<SEC-DOCUMENT>0001193125-25-230925.txt : 20251006
<SEC-HEADER>0001193125-25-230925.hdr.sgml : 20251006
<ACCEPTANCE-DATETIME>20251006073015
ACCESSION NUMBER:		0001193125-25-230925
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251005
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251006
DATE AS OF CHANGE:		20251006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Stoke Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001623526
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				471144582
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38938
		FILM NUMBER:		251375616

	BUSINESS ADDRESS:	
		STREET 1:		45 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		781-430-8200

	MAIL ADDRESS:	
		STREET 1:		45 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASOthera Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20141028
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d55930d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stok="http://www.stoketherapeutics.com/20251005" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-290">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-10-05_to_2025-10-05">0001623526</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="stok-20251005.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-10-05_to_2025-10-05"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-10-05</xbrli:startDate> <xbrli:endDate>2025-10-05</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-301">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt:datemonthdayyearen" id="ixv-302">October 5, 2025</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-303">Stoke Therapeutics, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt-sec:stateprovnameen" id="ixv-304">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-305">001-38938</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-306">47-1144582</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-307">45 Wiggins Ave</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-308">Bedford</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt-sec:stateprovnameen" id="ixv-309">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-310">01730</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-311">(781)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-312">430-8200</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt-sec:boolballotbox" id="ixv-313">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt-sec:boolballotbox" id="ixv-314">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt-sec:boolballotbox" id="ixv-315">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt-sec:boolballotbox" id="ixv-316">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-317">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-318">STOK</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt-sec:exchnameen" id="ixv-319">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-10-05_to_2025-10-05" format="ixt-sec:boolballotbox" id="ixv-320">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;5.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer Appointment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;5, 2025, the Board of Directors (the &#8220;Board&#8221;) of Stoke Therapeutics, Inc. (the &#8220;Company&#8221;) appointed Ian F. Smith, who has been serving as the Company&#8217;s Interim Chief Executive Officer since March&#160;19, 2025, as the Company&#8217;s permanent Chief Executive Officer and principal executive officer (the &#8220;Smith Appointment&#8221;), effective as of October&#160;6, 2025 (the &#8220;Effective Date&#8221;). Mr.&#160;Smith will also remain a member of the Board, serving as a Class&#160;II director with a term expiring at the Company&#8217;s 2027 Annual Meeting of Stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Smith, age 59, served as the Company&#8217;s Interim Chief Executive Officer since March 2025 and as a member of the Board since September 2023. Prior to that, Mr.&#160;Smith served as a consultant to the Company since June 2023. Mr.&#160;Smith is the Chair of the Board of Directors for Rivus&#160;Pharmaceutical, a position he has held since September 2023 and is Executive Chair of the Board of Directors of Solid Biosciences, which position he has held since April 2020. Mr.&#160;Smith also serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021. He has also served as a member of the Board of Directors of Foghorn Therapeutics since April 2021, Alkeus Therapeutics since 2022, Odyssey Therapeutics since 2024, and Areteia Therapeutics since March 2025. Prior to his current roles, Mr.&#160;Smith served as Executive Chair of the Board of Directors of Viacyte, a private biotechnology company, from July 2019 to September 2022. He was Executive Vice President and Chief&#160;Operating Officer of Vertex Pharmaceuticals, from September 2017 to January 2019, and, before that, served as Chief Financial Officer from October&#160;2001 to September 2017. Mr.&#160;Smith holds a B.A. with honors in accounting and finance from Manchester Metropolitan (UK). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Mr.&#160;Smith and any other persons, pursuant to which he was appointed as Chief Executive Officer and principal executive officer, there are no family relationships among any of the Company&#8217;s directors or executive officers and Mr.&#160;Smith, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the appointment of Mr.&#160;Smith as Chief Executive Officer, the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;) recommended, and the Board approved, the Company&#8217;s entry into an employment agreement (the &#8220;Smith Employment Agreement&#8221;) with Mr.&#160;Smith, which includes the following terms: (i)&#160;an initial annual base salary of $715,000 per year (the &#8220;Initial Base Salary&#8221;), (ii)&#160;an annual discretionary bonus of up to 65% of the Initial Base Salary, provided, however that Mr.&#160;Smith will not be eligible to receive an annual bonus for 2025, (iii) a <span style="white-space:nowrap">sign-on</span> bonus of $500,000, which is repayable if Mr.&#160;Smith resigns or is terminated for cause within 12 months, (iv)&#160;a performance bonus of $500,000, to be earned if certain performance metrics have been achieved, (v)&#160;an option to purchase up to 570,000 shares of the Company&#8217;s common stock (the &#8220;Option Award&#8221;), with 1/4th of the shares underlying the Option Award vesting and becoming exercisable on <span style="white-space:nowrap">the&#160;one-year&#160;anniversary</span> of the Effective Date and 1/48th of the shares underlying the Option Award vesting and becoming exercisable on a monthly basis thereafter, and (vi)&#160;a restricted stock unit for 380,000 shares of the Company&#8217;s common stock, which vests in four equal annual installments on the anniversary of the Effective Date, among other benefits. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, in the event Mr.&#160;Smith experiences a termination of his employment without &#8220;cause&#8221; or he resigns for &#8220;good reason&#8221; (each as defined in the Smith Employment Agreement), provided that he executes and makes effective a release of claims against the Company and its affiliates, he will become entitled to (i)&#160;continued base salary for 12 months, payable in accordance with the Company&#8217;s standard payroll practices, (ii)&#160;his annual target bonus based on the achievement level of the performance metrics, as determined by the Board, paid in a single <span style="white-space:nowrap">lump-sum,</span> (iii)&#160;his performance bonus, if the performance metrics have been met and the bonus has not yet been paid, (iv)&#160;premium payments for continued healthcare coverage for up to 12&#160;months and (v) 12&#160;months accelerated vesting of his then outstanding equity awards. Mr.&#160;Smith and the Company also entered into a change of control and severance agreement (the &#8220;Smith Change of Control and Severance Agreement&#8221;), and in the event he experiences a termination without &#8220;cause&#8221; or he resigns for &#8220;good reason&#8221; during the&#160;period commencing three months prior to and ending 12 months following a change in control, then in lieu of the foregoing, he would become entitled to (i)&#160;continued base salary for 18 months, payable in accordance with the Company&#8217;s standard payroll practices; (ii)&#160;150% of his annual target bonus, payable in a single <span style="white-space:nowrap">lump-sum;</span> (iii)&#160;premium payments for continued healthcare coverage for up to 18; and (iv)&#160;100% accelerated vesting of his then-outstanding equity awards. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Mr.&#160;Smith&#8217;s appointment as the Company&#8217;s interim Chief Executive officer, he was granted an option to purchase up to 238,420 shares of the Company&#8217;s common stock, which, pursuant to their terms vested monthly during his interim services and in full at the conclusion of his interim services. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Smith is also party to the Company&#8217;s standard form of indemnification agreement. The form of the indemnification agreement was previously filed by the Company as Exhibit 10.1 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1</span> filed with the Securities and Exchange Commission on June&#160;7, 2019, and incorporated by reference herein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interim Executive Chair of the Board Resignation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Smith Appointment, and as of the Effective Date, Dr.&#160;Tzianabos resigned from the role of Interim Executive Chair of the Board and resumed his status as an independent director and will remain Chair of the Board. Dr.&#160;Tzianabos will also resume his role as a member of the Compensation Committee and as a member of the Audit Committee of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Tzianabos is also party to the Company&#8217;s standard form of indemnification agreement. The form of the indemnification agreement was previously filed by the Company as Exhibit 10.1 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1</span> filed with the Securities and Exchange Commission on June&#160;7, 2019, and incorporated by reference herein. In connection with the resumption of his status as an independent director, Dr.&#160;Tzianabos will receive cash compensation pursuant to the Company&#8217;s <span style="white-space:nowrap">non-employee</span> director compensation policy, and he will be eligible for an equity grant under such policy in 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the Smith Employment Agreement and Smith Change of Control and Severance Agreement do not purport to be complete and are qualified in their entirety by reference to the complete text of each of the Smith Employment Agreement and Smith Change of Control and Severance Agreement. Copies of the Smith Employment Agreement and Smith Change of Control and Severance Agreement are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Description</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d55930dex101.htm">Executive Employment Agreement, by and between the Company and Ian F. Smith, effective as of October&#160;6, 2025</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d55930dex102.htm">Change of Control and Severance Agreement, by and between the Company and Ian F. Smith, effective as of October&#160;6, 2025</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">STOKE THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;6, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas E. Leggett</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Thomas E. Leggett</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Chief Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d55930dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXECUTIVE EMPLOYMENT AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Executive Employment Agreement (the &#8220;Agreement&#8221;) is made and entered into this 6th day of October, 2025 (the
&#8220;Effective Date&#8221;), by and between Stoke Therapeutics, Inc. (&#8220;Stoke&#8221;), and <B>Ian Smith </B>(&#8220;Executive&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, Stoke wishes to employ Executive to serve as its Chief Executive Officer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, Executive represents that Executive possesses the necessary skills to perform the duties of this position and that
Executive has no obligation to any other person or entity which would prevent, limit or interfere with Executive&#8217;s ability to do so; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, Executive and Stoke desire to supersede the Interim CEO letter agreement dated March&nbsp;16, 2025 between Executive
and Stoke (the &#8220;Interim Employment Agreement&#8221;) and enter into this Executive Employment Agreement to assure the harmonious performance of the affairs of Stoke. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration of the mutual promises, covenants, terms, provisions, and conditions contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>Title and Duties</U>. Subject to the terms and conditions of this Agreement, Executive&#8217;s position with Stoke shall
be Chief Executive Officer (&#8220;CEO&#8221;) reporting to Stoke&#8217;s Board of Directors (the &#8220;Board&#8221;). Executive shall provide the services described hereunder in Stoke&#8217;s office in Bedford, MA, <U>provided</U> that Executive
shall be permitted to provide services in other locations as agreed upon by Executive and the Board. Executive accepts such employment upon the terms and conditions set forth herein, and agrees to perform to the best of Executive&#8217;s ability the
duties normally associated with such position and as reasonably determined by the Board in its sole discretion. While serving as Chief Executive Officer hereunder, Executive shall devote all of Executive&#8217;s business time and energies to the
business and affairs of Stoke, and Executive will not render services to any other business without the prior approval of the Board, other than continuing service on the other boards of directors on which Executive currently serves on the date
hereof and serving as a senior advisor to Bain Capital Life Sciences; <U>provided</U>, that nothing contained in this Section&nbsp;1 shall prevent or limit: (a)&nbsp;Executive&#8217;s right to manage Executive&#8217;s personal investments on
Executive&#8217;s own personal time, including, without limitation the right to make passive investments in securities of (i)&nbsp;any entity which Executive does not control, directly or indirectly, and which does not compete with Stoke, or
(ii)&nbsp;any publicly held entity, so long as Executive&#8217;s aggregate direct and indirect interest does not exceed two percent (2%) of the issued and outstanding securities of any class of securities of such publicly held entity; and
(b)&nbsp;Executive&#8217;s participation in civic and charitable activities, including as a member of a board of a civic or charitable organization, so long as such activities do not interfere with Executive&#8217;s performance of Executive&#8217;s
duties hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Term; Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Term</U>. Executive is currently employed by Stoke pursuant to the terms of the Interim Employment Agreement, and will
continue employment with Stoke pursuant to the terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of this Agreement commencing on October&nbsp;6, 2025 (the &#8220;Commencement Date&#8221;) and shall continue until terminated hereunder by either party (such term of employment shall be referred
to herein as the &#8220;Term&#8221;). Executive&#8217;s employment with Stoke shall be <FONT STYLE="white-space:nowrap">at-will</FONT> and may be terminated by Executive or Stoke at any time, subject to the terms and conditions in this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Termination by Stoke</U>. Notwithstanding anything else contained in this Agreement, Stoke may terminate
Executive&#8217;s employment hereunder as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>For Cause</U>. Stoke may terminate
Executive&#8217;s employment for Cause (as defined below) by written notice by Stoke to Executive that Executive&#8217;s employment is being terminated for Cause, which termination shall be effective on the date of such notice or such later date as
specified in writing by Stoke, <U>provided</U> that if Executive has cured the circumstances giving rise to Cause (as such cure right may be applicable pursuant to the terms and conditions set forth below) then such termination shall not be
effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>Without Cause</U>. Stoke may terminate Executive&#8217;s employment without Cause, by
written notice by Stoke to Executive that Executive&#8217;s employment is being terminated without Cause, which termination shall be effective on the date of such notice or such later date as specified in writing by Stoke. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this Agreement, &#8220;Cause&#8221; shall mean: (A)&nbsp;fraud, embezzlement, or illegal
misconduct in connection with Executive&#8217;s duties under this Agreement; (B)&nbsp;commission of a felony involving fraud, dishonesty or breach of trust; (C)&nbsp;willful misconduct or gross negligence in the performance of the duties delegated
to Executive that results in (or would reasonably be expected to result in) material harm to the business or reputation of Stoke; (D)&nbsp;material breach of this Agreement; or (E)&nbsp;material breach of Executive&#8217;s <FONT
STYLE="white-space:nowrap">Non-Competition,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicitation,</FONT> <FONT STYLE="white-space:nowrap">Non-Disclosure,</FONT> and Intellectual Property Agreement (as described below); <U>provided</U> that
&#8220;Cause&#8221; shall not be deemed to have occurred pursuant to subsection (D)&nbsp;hereof unless Executive has first received written notice specifying in reasonable detail the particulars of such ground and that Stoke intends to terminate
Executive&#8217;s employment hereunder for such ground, and if such ground is curable, Executive has failed to cure such ground within a period of thirty (30)&nbsp;days from the date of his receipt of such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Termination by Executive</U>. Notwithstanding anything else contained in this Agreement, Executive may terminate
Executive&#8217;s employment hereunder as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>For Good Reason</U>. Executive may terminate
Executive&#8217;s employment for Good Reason (as defined below) by written notice by Executive to Stoke that Executive is terminating Executive&#8217;s employment for Good Reason, which termination shall be effective thirty (30)&nbsp;days after the
date of such notice; <U>provided</U> that if Stoke has cured the circumstances giving rise to Good Reason then such termination shall not be effective; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>Without Good Reason</U>. Executive may terminate Executive&#8217;s employment without Good Reason by
written notice by Executive to Stoke that Executive is terminating Executive&#8217;s employment, which termination shall be effective ninety (90)&nbsp;days after the date of such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this Agreement, &#8220;Good
Reason&#8221; shall mean: (A)&nbsp;a reduction in Executive&#8217;s then-current Base Salary of ten percent (10%) or more, provided that such reduction is unique to Executive and not to all similarly situated executives of Stoke; (B)&nbsp;a material
diminution of Executive&#8217;s responsibilities, authority, duties or his Executive ceasing to report to the Board; (C)&nbsp;Executive is not the Chief Executive Officer of the parent company following any Change of Control (as that term is defined
in Executive&#8217;s Change of Control Severance Agreement); (D) a material change in the geographic location at which the Executive provides services to Stoke outside of a fifty (50)&nbsp;mile radius from the then-current location; (E)&nbsp;any
action or inaction by Stoke that constitutes a material breach of this Agreement, including but not limited to, any modification by the Board of Executive&#8217;s remote/hybrid work arrangement which exists as of the Commencement Date; or
(F)&nbsp;any directive to Executive by the Board to engage in a willful violation of law; <U>provided</U> that &#8220;Good Reason&#8221; shall not be deemed to have occurred unless: (1)&nbsp;Executive provides Stoke with written notice that
Executive intends to terminate Executive&#8217;s employment hereunder for one of the grounds set forth above within thirty (30)&nbsp;days of such ground first occurring, (2)&nbsp;if such ground is capable of being cured, Stoke has failed to cure
such ground within a period of thirty (30)&nbsp;days from the date of such written notice, and (3)&nbsp;Executive terminates Executive&#8217;s employment within seventy five (75)&nbsp;days from the date that Good Reason first occurs. For purposes of
clarification, the above-listed conditions shall apply separately to each occurrence of Good Reason and failure to adhere to such conditions in the event of Good Reason shall not disqualify Executive from asserting Good Reason for any subsequent
occurrence of Good Reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Termination Due to Executive&#8217;s Death or Disability</U>. Notwithstanding anything
else contained in this Agreement, Stoke may terminate Executive&#8217;s employment immediately upon Executive&#8217;s death, or due to Executive&#8217;s Disability (as defined below) by written notice to Executive that Executive&#8217;s employment
is being terminated as a result of Executive&#8217;s Disability, which termination shall be effective on the date of such notice or such later date as specified in writing by Stoke. For the purposes of this Agreement, &#8220;Disability&#8221; shall
mean Executive&#8217;s incapacity or inability to perform Executive&#8217;s duties and responsibilities as contemplated herein for one hundred twenty (120)&nbsp;days or more within any one (1)&nbsp;year period (cumulative or consecutive), because
Executive&#8217;s physical or mental health has become so impaired as to make it impossible or impractical for Executive to perform the duties and responsibilities contemplated hereunder. Determination of Executive&#8217;s physical or mental health
shall be determined by Stoke after consultation with a medical expert appointed by mutual agreement between Stoke and Executive who has examined Executive. Executive hereby consents to such examination and consultation regarding Executive&#8217;s
health and ability to perform as aforesaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Compensation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Base Salary</U>. While Executive is employed hereunder, Executive shall earn a base salary at the annual rate of
<B>$715,000.00</B> (the &#8220;Base Salary&#8221;). The Base Salary shall be payable in substantially equal periodic installments, in accordance with Stoke&#8217;s payroll practices as in effect from time to time. Stoke shall deduct from each such
installment all amounts required to be deducted or withheld under applicable law or under any employee benefit plan in which Executive participates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Annual Bonus</U>. Executive shall be eligible to receive an annual
cash bonus with a target amount equal to <B>65%</B> of Executive&#8217;s Base Salary, (the &#8220;Annual Bonus&#8221;); provided that Executive will not be eligible to receive any portion of the 2025 annual bonus. The amount of the Annual Bonus
shall be based on factors such as Executive&#8217;s work performance, Stoke&#8217;s financial performance, Stoke&#8217;s business forecasts, Stoke&#8217;s determination of Executive&#8217;s achievement of milestones for the applicable year, and
economic conditions generally. The actual amount of the Annual Bonus shall be determined by the Board (or its Compensation Committee) in its sole discretion. Executive&#8217;s Annual Bonus shall be paid by the fifteenth day of the third month
following Executive&#8217;s or Stoke&#8217;s taxable year in which it is earned, whichever is later. Executive must be employed by Stoke on the last day of such fiscal year to which such Annual Bonus relates, to be deemed as having earned the Annual
Bonus. Stoke shall deduct from the Annual Bonus all amounts required to be deducted or withheld under applicable law or under any employee benefit plan in which Executive participates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U><FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus</U>. Executive will be entitled to receive a <FONT
STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of <B>$500,000.00 </B>(the <FONT STYLE="white-space:nowrap">&#8220;Sign-On</FONT> Bonus&#8221;), less applicable taxes, deductions and withholdings,
payable in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> within thirty days following the Commencement Date, subject to Executive&#8217;s continued employment through such payment date. If Executive resigns his employment, or Stoke
terminates Executive&#8217;s employment for Cause, within the twelve (12)&nbsp;month period following the Commencement Date, Executive shall be required to repay the <FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus on a &#8220;gross&#8221;
basis (i.e., it will not be reduced for any federal, state or local income, excise, employment or other withholding taxes previously withheld by Stoke or paid by Executive). Executive agrees to repay the
<FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus within ten (10)&nbsp;calendar days following the termination of Executive&#8217;s employment and, if and to the extent permissible under applicable law, authorizes Stoke to withhold from any
amounts otherwise owed to Executive to effect such repayment. Notwithstanding the foregoing, subject to Executive&#8217;s satisfaction of the release requirement in Section&nbsp;4(c) below, Executive shall not be required to repay any portion of the
<FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus in the event of Stoke terminates Executive&#8217;s employment without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Performance Bonus</U>. Executive shall receive a <FONT STYLE="white-space:nowrap">one-time</FONT> performance bonus of
<B>$500,000.00 </B>(the &#8220;Performance Bonus&#8221;), less applicable taxes, deductions and withholdings, upon achievement of certain Performance Metrics which shall be mutually agreed-upon between Executive and the Board. Executive and Stoke
acknowledge that this Agreement is contingent upon a mutual agreement between Executive and the Board regarding the certain Performance Metrics upon which the Performance Bonus shall be based. The Performance Bonus will be paid in a single <FONT
STYLE="white-space:nowrap">lump-sum</FONT> within fourteen (14)&nbsp;days following the determination of the Board that Executive has achieved the mutually agreed-upon Performance Metrics. Except as otherwise provided in this Agreement, payment of
the Performance Bonus is subject to Executive&#8217;s employment on such payment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Equity</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Stock Options:</U> On the second business day following the Commencement Date (the &#8220;Equity Grant
Date&#8221;), and subject to the Board&#8217;s approval, Stoke shall grant Executive an option to purchase <B>570,000</B> shares of Stoke&#8217;s common stock (the &#8220;Option Award&#8221;) under Stoke&#8217;s 2019 Equity Incentive Plan (the
&#8220;Plan&#8221;). The Option Award shall have an exercise price equal to the closing price of Stoke&#8217;s common stock on the Equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Grant Date. The Option Award shall be an &#8220;incentive stock option&#8221; to the extent permitted under the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). Subject to the
Board&#8217;s approval as described above and Executive&#8217;s continued employment by Stoke, the Option Award shall vest as to one fourth (1/4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) of the total number of shares subject to the
Option Award on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Commencement Date, and one forty-eighth (1/48<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) of the total number of shares subject to the Option Award
shall vest in monthly installments thereafter on the same day of the month as the Commencement Date (and if there is no corresponding day, on the last day of the month), with all shares subject to the Option Award being fully vested on the four-year
anniversary of the Commencement Date. Vesting is contingent on Executive&#8217;s continued employment by Stoke and shall be subject to the terms and conditions of the Plan and the written agreement governing the Option Award except as explicitly set
forth in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>RSUs:</U> On the Equity Grant Date, and subject to the Board&#8217;s
approval, Stoke shall grant the Executive <B>380,000</B> restricted stock units (the &#8220;RSUs&#8221;) under the Plan. The RSUs shall vest in four equal annual installments over a four-year period on each annual anniversary of the Commencement
Date. Vesting is contingent on Executive&#8217;s continued employment by Stoke and shall be subject to the terms and conditions of the Plan and the written agreement governing the RSUs except as explicitly set forth in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) <U>Annual Equity Grants:</U> Executive will be eligible to receive annual equity grants beginning in
calendar year 2026 consistent with Stoke&#8217;s normal business practice, with any such equity grants being determined by the Board (or its Compensation Committee) and, to the extent such grants are made, being on such terms and subject to such
conditions as the Board (or its Compensation Committee) shall determine in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <U>Fringe
Benefits</U>. Executive shall be entitled to participate in all benefit/welfare plans and fringe benefits provided to employees at the same level as Executive. Executive understands that, except when prohibited by applicable law, Stoke&#8217;s
benefit plans and fringe benefits may be amended by Stoke from time to time in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) <U>Vacation</U>.
Executive shall be eligible for Stoke&#8217;s unlimited vacation time policy, subject to its terms and conditions, as established or modified from time to time by Stoke. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) <U>Reimbursement of Expenses</U>. Stoke shall reimburse Executive for all ordinary and reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses incurred by Executive in furtherance of Stoke&#8217;s business in accordance with Stoke&#8217;s policies with respect thereto as in effect from
time to time. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A of the Code (&#8220;Section&nbsp;409A&#8221;) and the rules and regulations thereunder, including,
where applicable, the requirement that (i)&nbsp;any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement); (ii) the amount of expenses eligible for reimbursement
during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year; (iii)&nbsp;the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which
the expense is incurred; and (iv)&nbsp;the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Indemnification. Executive shall be eligible for coverage under Stoke
Directors&#8217; and Officers&#8217; (&#8220;D&amp;O&#8221;) insurance policies to the same extent and in the same manner to which Stoke&#8217;s similarly situated executives are entitled to coverage under Stoke D&amp;O insurance policies, subject
to the terms and conditions of any such Stoke D&amp;O insurance policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>Termination Payments; Severance
Benefit</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Payment of Accrued Obligations</U>. Regardless of the reason for any employment termination
hereunder, Stoke shall pay to Executive: (i)&nbsp;the portion of Executive&#8217;s Base Salary that has accrued prior to any termination of Executive&#8217;s employment and has not yet been paid; (ii)&nbsp;except in the event of Executive&#8217;s
termination for Cause, the amount of any Annual Bonus determined by the Board and payable from a prior year which remains unpaid by Stoke as of the date of the termination of employment; (iii)&nbsp;the amount of any expenses properly incurred by
Executive on behalf of Stoke prior to any such termination and has not yet been reimbursed (together, the &#8220;Accrued Obligations&#8221;) promptly following the effective date of termination, and otherwise within any timeframe required by law.
Executive&#8217;s entitlement to other compensation or benefits under any Stoke plan or policy shall be governed by and determined in accordance with the terms of such plan or policy, except as otherwise specified in this Agreement. In the event of
Stoke&#8217;s termination of Executive&#8217;s employment for Cause or Executive&#8217;s termination of Executive&#8217;s employment without Good Reason, Executive shall be eligible for the Accrued Obligations and shall not be eligible for any
severance or severance-type payments, other than as expressly set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Severance in the Event of
Termination Without Cause or Resignation for Good Reason</U>. Subject to the terms and conditions of Section&nbsp;4(c), in the event that Executive&#8217;s employment hereunder is terminated by Stoke without Cause or terminated by Executive for Good
Reason, then, in addition to the Accrued Obligations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Stoke shall continue to pay the
Executive&#8217;s Base Salary for a <B>twelve (12)</B>&nbsp;month period following the termination date of Executive&#8217;s employment (the &#8220;Separation Date&#8221;), with such payments to be made in accordance with Stoke&#8217;s normal
payroll practices and schedules, less all customary and required taxes and employment-related deductions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) Stoke shall pay Executive the Annual Bonus set forth in Section&nbsp;3(b) for the year in which the
termination occurs based on the achievement level of the factors described in Section&nbsp;3(b), as determined by the Board (or its Compensation Committee), paid in one lump sum, less all customary and required taxes and employment-related
deductions, within the time period described in Section&nbsp;3(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) To the extent the Board
determines in good faith that the mutually agreed-upon Performance Metrics referenced in Section&nbsp;3(d) have been achieved on or prior to the termination date of Executive&#8217;s employment, but the Performance Bonus set forth in
Section&nbsp;3(d) has not been paid to Executive, the Performance Bonus shall be paid within the time period described in Section&nbsp;3(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) In the event that Executive is eligible for coverage under a Stoke health insurance plan and Executive has
elected to have coverage thereunder and was covered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
thereunder prior to termination, and in the event that Executive chooses to exercise Executive&#8217;s right under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;)
to continue Executive&#8217;s participation in such plan, Stoke shall pay its normal share of the costs for such coverage for a period of up to <B>twelve (12)</B>&nbsp;months from the Separation Date, to the same extent that such insurance is
provided to persons then currently employed by Stoke. Stoke shall deduct from each of the installments due under Section&nbsp;4(b)(i) the portion of the monthly premium due from Executive in accordance with the terms of such coverage.
Notwithstanding any other provision of this Agreement, this obligation shall cease on the date Executive becomes eligible to receive health insurance benefits through any other employer, and Executive agrees to provide Stoke with written notice
immediately upon becoming eligible for such benefits. Executive&#8217;s acceptance of any payment on Executive&#8217;s behalf or coverage provided hereunder shall be an express representation to Stoke that Executive has no such eligibility. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) The portion of Executive&#8217;s then-outstanding unvested options to purchase shares of Company common
stock as well as any and all other stock-based awards granted to the Executive, including but not limited to stock bonus awards, restricted stock, restricted stock units or stock appreciation rights (the &#8220;Equity Awards&#8221;) that would have
vested during the twelve (12)&nbsp;month period following the Separation Date had Executive&#8217;s termination of employment not occurred shall vest on the Separation Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subsections (i)&nbsp;through (v) are referred to as the Severance Benefit. The Severance Benefit is expressly subject to the
conditions described above and in Section&nbsp;4(c) below. Any payment or benefit made as part of such Severance Benefit shall be paid less all customary and required taxes and employment-related deductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Conditions</U>. Stoke shall not be obligated to provide Executive with the Severance Benefit described in
Section&nbsp;4(b) unless and until Executive has executed without revocation a separation agreement in a form acceptable to Stoke, which must be signed by Executive, returned to Stoke and be enforceable and irrevocable no later than sixty
(60)&nbsp;days following Executive&#8217;s Separation Date (the &#8220;Review Period&#8221;), and which shall include, at a minimum, the provision of the Severance Benefit due from Stoke to Executive, a complete general release of claims against
Stoke and its affiliated entities and each of their officers, directors and employees, and terms relating to <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> <FONT STYLE="white-space:nowrap">non-competition,</FONT> confidentiality,
cooperation and other customary terms determined by Stoke. If Executive executes and does not revoke such agreement within the time provided in the Separation Agreement, then provision of the portion of the Severance Benefit specified in Sections
4(b)(i) through (iv)&nbsp;shall commence on the first (1st) regularly scheduled payroll date following the Review Period, <U>provided</U> that if the last day of the Review Period occurs in the calendar year following the year of termination, then
the payment shall not commence until January&nbsp;2 of such subsequent calendar year, and further <U>provided</U> that, as applied to Section&nbsp;4(b), the first payments/benefits shall include in a lump sum all amounts that were otherwise payable
to Executive from the Separation Date through such first payment. As stated in Stoke&#8217;s <FONT STYLE="white-space:nowrap">Non-Competition,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicitation,</FONT>
<FONT STYLE="white-space:nowrap">Non-Disclosure,</FONT> and Intellectual Property Agreement (described below), in the event Executive is eligible for garden leave or analogous payments in support of
<FONT STYLE="white-space:nowrap">non-competition</FONT> obligations, then Stoke reserves the right to offset the portions of the Severance Benefit specified in Sections 4(b)(i) through (iv)&nbsp;with such garden leave or analogous payments to the
extent permitted by applicable law (<I>i.e. </I>Stoke shall pay the greater of the severance or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
garden leave but not both). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>COBRA</U>. If the payment of any
COBRA or health insurance premiums by Stoke on behalf of Executive as described herein would otherwise violate any applicable nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable Care
Act of 2010, together with the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;Act&#8221;) or Section&nbsp;105(h) of the Code, the COBRA premiums paid by Stoke shall be treated as taxable payments (subject to customary
and required taxes and employment-related deductions) and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation under the Act or Section&nbsp;105(h) of the Code. If Stoke determines
in its sole discretion that it cannot provide the COBRA benefits described herein under Stoke&#8217;s health insurance plan without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service
Act), Stoke shall in lieu thereof provide to Executive a taxable <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment in an amount equal to the sum of the monthly (or then remaining) COBRA premiums that Executive would be required to pay to
maintain Executive&#8217;s group health insurance coverage in effect on the Separation Date for the remaining portion of the period for which Executive shall receive the payments described in Section&nbsp;4(b) above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>No Other Payments or Benefits Owing</U>. The payments and benefits set forth in this Section&nbsp;4 shall be the sole
amounts owing to Executive upon termination of Executive&#8217;s employment for the reasons set forth above and Executive shall not be eligible for any other payments or other forms of compensation or benefits except as may be provided in the
Executive&#8217;s Change of Control Severance Agreement. The payments and benefits set forth in this Section shall be the sole remedy, if any, available to Executive in the event that Executive brings any claim against Stoke relating to the
termination of Executive&#8217;s employment under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>Non-Competition, Non-Solicitation, Non-Disclosure
Agreement</U>. In light of the competitive and proprietary aspects of the business of Stoke, and as a condition of Executive&#8217;s employment hereunder, Executive agrees to sign and abide by Stoke&#8217;s
<FONT STYLE="white-space:nowrap">Non-Competition,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicitation,</FONT> <FONT STYLE="white-space:nowrap">Non-Disclosure,</FONT> and Intellectual Property Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>Code Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) In the event that the payments or benefits set forth in Section&nbsp;4 constitute
<FONT STYLE="white-space:nowrap">&#8220;non-qualified</FONT> deferred compensation&#8221; subject to Section&nbsp;409A, then the following conditions apply to such payments or benefits: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Any termination of Executive&#8217;s employment triggering payment of benefits under Section&nbsp;4 must
constitute a &#8220;separation from service&#8221; under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h)</FONT> before distribution of such benefits can commence. To the extent that the
termination of Executive&#8217;s employment does not constitute a separation of service under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h)</FONT> (as the result of further services that
are reasonably anticipated to be provided by Executive to Stoke at the time Executive&#8217;s employment terminates), any such payments under Section&nbsp;4 that constitute deferred compensation under Section&nbsp;409A shall be delayed until after
the date of a subsequent event constituting a separation of service </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h).</FONT> For purposes of clarification, this Section&nbsp;6(a) shall not cause
any forfeiture of benefits on Executive&#8217;s part, but shall only act as a delay until such time as a &#8220;separation from service&#8221; occurs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) Notwithstanding any other provision with respect to the timing of payments under Section&nbsp;4 if, at the
time of Executive&#8217;s termination, Executive is deemed to be a &#8220;specified employee&#8221; of Stoke (within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code), then limited only to the extent necessary to comply with the requirements
of Section&nbsp;409A, any payments to which Executive may become entitled under Section&nbsp;4 which are subject to Section&nbsp;409A (and not otherwise exempt from its application) shall be withheld until the first (1st) business day of the seventh
(7th) month following the termination of Executive&#8217;s employment, at which time Executive shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to Executive under the terms of Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) It is intended that each installment of the payments and benefits provided under Section&nbsp;4 shall be treated as a
separate &#8220;payment&#8221; for purposes of Section&nbsp;409A. Neither Stoke nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by
Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Notwithstanding any other provision of this Agreement to the contrary, this Agreement shall be
interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section&nbsp;409A, or the payment of increased taxes, excise taxes or other penalties under Section&nbsp;409A. The parties intend this
Agreement to be in compliance with Section&nbsp;409A. Executive acknowledges and agrees that Stoke does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not
limited to consequences related to Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>General</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Notices</U>. Except as otherwise specifically provided herein, any notice required or permitted by this Agreement shall
be in writing and shall be delivered as follows with notice deemed given as indicated: (i)&nbsp;by personal delivery when delivered personally; (ii)&nbsp;by overnight courier upon written verification of receipt; (iii)&nbsp;by certified or
registered mail, return receipt requested, upon verification of receipt; or (iv)&nbsp;by <FONT STYLE="white-space:nowrap">e-mail,</FONT> upon acknowledgement of receipt from the receiving party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Notices to Executive shall be sent to the address specified below, or the last known address in Stoke&#8217;s records.
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Notices to Stoke shall be sent to: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Jonathan Allan, General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stoke Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">45 Wiggins Ave </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Bedford, MA 01730 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Wendy Baccari, Executive Director, HR Operations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stoke Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">45 Wiggins Ave </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Bedford, MA 01730 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy to: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">701 Pennsylvania Avenue NW #900 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Washington, DC 20004 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Email: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fax: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attn: David Barmak, Esq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Modifications and Amendments</U>. The terms and provisions of this Agreement may be modified or amended only by written
agreement executed by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Waivers and Consents</U>. The terms and provisions of this Agreement may
be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent
with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing
waiver or consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Assignment</U>. Stoke may assign its rights and obligations hereunder to any person or entity
that succeeds to all or substantially all of Stoke&#8217;s business or that aspect of Stoke&#8217;s business in which Executive is principally involved. Executive may not assign Executive&#8217;s rights and obligations under this Agreement without
the prior written consent of Stoke. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Governing Law; Jury Waiver</U>. This Agreement and the rights and obligations
of the parties hereunder shall be construed in accordance with and governed by the law of the Commonwealth of Massachusetts without giving effect to the conflict of law principles thereof. Any legal action or proceeding with respect to this
Agreement shall be brought in the courts of the Commonwealth of Massachusetts or the United States of America for the District of Massachusetts. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in
respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts. ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT SHALL BE RESOLVED BY A JUDGE ALONE AND EACH OF STOKE
AND EXECUTIVE WAIVES ANY RIGHT TO A JURY TRIAL THEREOF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <U>Headings and Captions</U>. The headings and captions of
the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) <U>Entire Agreement</U>. This Agreement, together with the other agreements expressly
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
referenced herein, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and
understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms
and provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) <U>Counterparts</U>. This Agreement may be executed in two or more counterparts,
and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. For all purposes signed counterparts delivered by fax or other digital means
(e.g., .pdf) shall be treated as an original. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ian Smith</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">STOKE THERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Ian Smith</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Arthur Tzianabos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Signature</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By: Arthur Tzianabos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: Interim Executive Chair</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: October 5, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d55930dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CHANGE OF CONTROL SEVERANCE AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Change of Control Severance Agreement (the &#8220;Agreement&#8221;), is made and entered into this 6th day of October,
2025 (the &#8220;Effective Date&#8221;), by and between Stoke Therapeutics, Inc. (&#8220;Stoke&#8221;), and <B>Ian Smith</B> (&#8220;Executive&#8221;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Recitals</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">R-1.</FONT> Stoke and Executive are parties to an Employment Agreement dated on or about the
date hereof, (the &#8220;Employment Agreement,&#8221; which term shall include the Employment Agreement as it may be amended from time to time hereafter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">R-2.</FONT> Stoke wishes to provide Executive with certain promises and benefits in the event
Stoke terminates Executive&#8217;s employment without Cause or Executive terminates Executive&#8217;s employment for Good Reason, within the period beginning ninety (90)&nbsp;days prior to and ending one (1)&nbsp;year following a Change of Control.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration of the mutual promises, terms and conditions in this Agreement and other good and
valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) All capitalized terms used in this Agreement and not otherwise defined herein shall have the meaning ascribed to them in
Executive&#8217;s Employment Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Change of Control</U>. As used in this Agreement, a &#8220;Change of
Control&#8221; shall mean the occurrence of any of the following events, provided that, in each case of (i)&nbsp;and (ii), the transaction (including any series of transactions) also qualifies as a change in control under U.S. Treasury Regulation <FONT
STYLE="white-space:nowrap">1.409A-3(i)(5):</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) <U>Ownership</U>. Any &#8220;Person&#8221; (as such
term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the &#8220;Beneficial Owner&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under said Act), directly or indirectly, of
securities of Stoke representing fifty percent (50%) or more of the total voting power represented by Stoke&#8217;s then outstanding voting securities (excluding for this purpose any such voting securities held by Stoke, or any affiliate, parent or
subsidiary of Stoke, or by any employee benefit plan of Stoke) pursuant to a transaction or a series of related transactions which Stoke&#8217;s Board of Directors (the &#8220;Board&#8221;) does not approve; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) <U>Merger/Sale of Assets</U>. (A)&nbsp;A merger or consolidation of Stoke whether or not approved by the
Board, other than a merger or consolidation which would result in the voting securities of Stoke outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity or the parent of such corporation) at least fifty percent (50%) of the total voting power represented by the voting securities of Stoke or such surviving entity or parent of such corporation, as the case may be, outstanding
immediately after such merger </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or consolidation; or (B)&nbsp;the sale or disposition by Stoke of all or substantially all of Stoke&#8217;s assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Change of Control Severance Benefit</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) In the event that Executive&#8217;s employment with Stoke is terminated by Stoke without Cause or terminated by Executive
for Good Reason within the period beginning ninety (90)&nbsp;days prior to and ending one (1)&nbsp;year following a Change of Control, then, in addition to any Accrued Obligations and in lieu of any Severance Benefit otherwise payable to the
Executive under Executive&#8217;s Employment Agreement and subject to the Executive signing and not revoking the separation agreement and release of claims provided for in Section&nbsp;4 of this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Stoke shall provide Executive with a payment in an amount equal to Executive&#8217;s Base Salary for an <B>eighteen
(18)</B><B></B><B>&nbsp;month</B> <B>period</B>, with such payment to be made either in a lump sum, or in substantially equal installments in accordance with Stoke&#8217;s normal payroll practices and schedules (such method of payment shall be
determined by Stoke in its sole discretion), less all customary and required taxes and employment-related deductions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)
Stoke shall provide Executive with a payment in an amount equal to <B>one hundred and fifty percent</B> <B>(150%)</B> of Executive&#8217;s then-current target amount of Annual Bonus for the year in which Executive&#8217;s termination date occurs
(the &#8220;Separation Date&#8221;), paid in one lump sum amount within sixty (60)&nbsp;days following the Separation Date, less all customary and required taxes and employment-related deductions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) In the event that Executive is eligible for coverage under a Stoke health insurance plan, Executive was covered
thereunder prior to termination, and Executive chooses to exercise Executive&#8217;s rights under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;) to continue Executive&#8217;s participation in such plan, Stoke shall
pay the premiums charged to continue Executive&#8217;s health insurance coverage pursuant to COBRA for a period of up to <B>eighteen (18)</B><B>&nbsp;months</B> from termination, to the same extent that such insurance is provided to persons then
currently employed by Stoke. Notwithstanding any other provision of this Agreement, this obligation shall cease on the date Executive becomes eligible to receive health insurance benefits through any other employer, and Executive agrees to provide
Stoke with written notice immediately upon becoming eligible for such benefits. Executive&#8217;s acceptance of any payment on Executive&#8217;s own behalf or coverage provided hereunder shall be an express representation to Stoke that Executive has
no such eligibility. If Stoke determines in its sole discretion that it cannot provide the COBRA benefits described herein under Stoke&#8217;s health insurance plan without potentially violating applicable law (including, without limitation,
Section&nbsp;2716 of the Public Health Service Act), Stoke shall in lieu thereof provide to Executive a taxable <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment in an amount equal to the sum of the monthly (or then remaining) COBRA premiums
that Executive would be required to pay to maintain Executive&#8217;s group health insurance coverage in effect on the Separation Date for the remaining portion of the period for which Executive shall receive the payments described herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) All equity awards granted to Executive and outstanding as of the Separation Date shall fully accelerate and vest, subject
to the terms of any applicable equity plan and equity agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Section&nbsp;2(a)(i)-2(a)(iv)</FONT> are
referred to as the &#8220;Change of Control Severance Benefit.&#8221; The Change of Control Severance Benefit is expressly subject to the conditions described in this Agreement, including but not limited to Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Exclusions</U>. In the event that Executive is eligible for the Change of Control Severance Benefit described in
Section&nbsp;2 of this Agreement, Executive shall not be eligible for, and shall not receive any severance payments or benefits under any other severance or separation agreement or policy, including but not limited to the Severance Benefit under
Executive&#8217;s Employment Agreement. In the event that Executive&#8217;s employment is terminated for any reason other than those outlined in Section&nbsp;2, then Executive shall not be eligible for, and shall not receive the Change of Control
Severance Benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>Separation Agreement, Release of Claims</U>. Stoke shall not be obligated to provide Executive
with the Change of Control Severance Benefit unless and until (a)&nbsp;the consummation of the Change of Control; and (b)&nbsp;Executive has executed, without revocation a separation agreement in a form acceptable to Stoke, which must be signed by
Executive, returned to Stoke and be enforceable and irrevocable no later than sixty (60)&nbsp;days following Executive&#8217;s Separation Date (the &#8220;Review Period&#8221;), and which shall include, at a minimum, the provision of the Change of
Control Severance Benefit due from Stoke to Executive, a complete general release of claims against Stoke and its affiliated entities and each of their officers, directors and employees, and terms relating to
<FONT STYLE="white-space:nowrap">non-disparagement,</FONT> <FONT STYLE="white-space:nowrap">non-competition</FONT> (if applicable), confidentiality, cooperation and other customary terms determined by Stoke. If Executive executes and does not revoke
such agreement within the time provided in the separation agreement, then the Change of Control Severance Benefit shall be paid either: (i)&nbsp;in one lump sum amount on the first (1st) regularly scheduled payroll date following the Review Period;
or (ii)&nbsp;in substantially equal installments commencing on the first (1st) regularly scheduled payroll date following the Review Period, <U>provided</U> that, as applied to <FONT STYLE="white-space:nowrap">Section&nbsp;2(a)(i)-2(a)(iv),</FONT>
the first payments/benefits shall include in a lump sum all amounts that were otherwise payable to Executive from the Separation Date through such first payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>Sections 409A and 280G of the Code</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) In the event that the payments or benefits set forth in Section&nbsp;2 constitute
<FONT STYLE="white-space:nowrap">&#8220;non-qualified</FONT> deferred compensation&#8221; subject to Section&nbsp;409A, then the following conditions apply to such payments or benefits: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Any termination of Executive&#8217;s employment triggering payment of Change of Control Severance Benefit
under Section&nbsp;2 must constitute a &#8220;separation from service&#8221; under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h)</FONT> before distribution of such benefits can commence.
To the extent that the termination of Executive&#8217;s employment does not constitute a separation of service under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h)</FONT> (as the result
of further services that are reasonably anticipated to be provided by Executive to Stoke at the time Executive&#8217;s employment terminates), any such payments under Section&nbsp;2 that constitute deferred compensation under Section&nbsp;409A shall
be delayed until after the date of a subsequent event constituting a separation of service under Section&nbsp;409A(a)(2)(A)(i) of the Code and Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.409A-1(h).</FONT> For purposes of clarification, this
Section&nbsp;5(a) shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
not cause any forfeiture of benefits on Executive&#8217;s part, but shall only act as a delay until such time as a &#8220;separation from service&#8221; occurs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) Notwithstanding any other provision with respect to the timing of payments under Section&nbsp;2 if, at the
time of Executive&#8217;s termination, Executive is deemed to be a &#8220;specified employee&#8221; of Stoke (within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code), then limited only to the extent necessary to comply with the requirements
of Section&nbsp;409A, any payments to which Executive may become entitled under Section&nbsp;2 which are subject to Section&nbsp;409A (and not otherwise exempt from its application) shall be withheld until the first (1st) business day of the seventh
(7th) month following the termination of Executive&#8217;s employment, at which time Executive shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to Executive under the terms of Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) It is intended that each installment of the payments and benefits provided under Section&nbsp;2 shall be treated as a
separate &#8220;payment&#8221; for purposes of Section&nbsp;409A. Neither Stoke nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by
Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Notwithstanding any other provision of this Agreement to the contrary, this Agreement shall be
interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section&nbsp;409A, or the payment of increased taxes, excise taxes or other penalties under Section&nbsp;409A. The parties intend this
Agreement to be in compliance with Section&nbsp;409A. Executive acknowledges and agrees that Stoke does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not
limited to consequences related to Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) If any payment or benefit that Executive would receive under
this Agreement, when combined with any other payment or benefit Executive receives pursuant to a Change of Control (for purposes of this section, a &#8220;Payment&#8221;) would: (i)&nbsp;constitute a &#8220;parachute payment&#8221; within the
meaning of Section&nbsp;280G the Code; and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#8220;Excise Tax&#8221;), then such Payment shall be either: (A)&nbsp;the full amount of such
Payment; or (B)&nbsp;such lesser amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes and
the Excise Tax, results in Executive&#8217;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. With
respect to subsection (B), if there is more than one method of reducing the payment as would result in no portion of the Payment being subject to the Excise Tax, then Executive shall determine which method shall be followed, provided that if
Executive fails to make such determination within thirty (30)&nbsp;days after Stoke has sent Executive written notice of the need for such reduction, Stoke may determine the amount of such reduction in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>No Impact on Employment Status</U>. This Agreement is not intended to confer, and shall not be interpreted as
conferring, any additional employment rights on Executive and has no impact on either party&#8217;s right to terminate Executive&#8217;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>General</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Modifications and Amendments</U>. The terms and provisions of this Agreement may be modified or amended only by written
agreement executed by the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Waivers and Consents</U>. The terms and provisions of this Agreement may
be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent
with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing
waiver or consent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Assignment</U>. Stoke may assign its rights and obligations hereunder to any person or entity
that succeeds to all or substantially all of Stoke&#8217;s business or that aspect of Stoke&#8217;s business in which Executive is principally involved. Executive may not assign Executive&#8217;s rights and obligations under this Agreement without
the prior written consent of Stoke. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) <U>Governing Law; Jury Waiver</U>. This Agreement and the rights and obligations
of the parties hereunder shall be construed in accordance with and governed by the law of the Commonwealth of Massachusetts without giving effect to the conflict of law principles thereof. Any legal action or proceeding with respect to this
Agreement shall be brought in the courts of the Commonwealth of Massachusetts or the United States of America for the District of Massachusetts. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in
respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts. ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT SHALL BE RESOLVED BY A JUDGE ALONE AND EACH OF STOKE
AND EXECUTIVE WAIVES ANY RIGHT TO A JURY TRIAL THEREOF. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Headings and Captions</U>. The headings and captions of the
various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) <U>Entire Agreement</U>. This Agreement, together with the other agreements expressly referenced herein, embodies the
entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. The terms of this Agreement shall
replace any agreement, policy or practice which otherwise would obligate Stoke to provide any severance compensation and/or benefits to Executive in connection with a Change of Control, <U>provided</U> that it shall not be construed to otherwise
limit Executive&#8217;s rights to payments or benefits provided under any pension plan (as defined in ERISA), deferred compensation, stock, stock option or similar plan sponsored by Stoke. Notwithstanding the foregoing and for the avoidance of
doubt, any applicable stock option award agreement, other award agreement or equity incentive plan existing between Stoke and Executive, and any existing indemnity agreement or <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or similar agreement between Stoke and Executive shall remain in full force and effect and shall not be superseded by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) <U>Counterparts</U>. This Agreement may be executed in two or more
counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. For all purposes signed counterparts delivered by fax or other
digital means (e.g., .pdf) shall be treated as an original. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ian Smith</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Ian Smith</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Signature</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Date: October 5, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">STOKE THERAPEUTICS, INC.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Arthur Tzianabos</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By: Arthur Tzianabos</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:
Interim Executive Chair</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>stok-20251005.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/6/2025 10:05:29 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:stok="http://www.stoketherapeutics.com/20251005"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.stoketherapeutics.com/20251005"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="stok-20251005_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="stok-20251005_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>stok-20251005_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/6/2025 10:05:29 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>stok-20251005_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/6/2025 10:05:29 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="stok-20251005.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001623526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  05,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Stoke Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1144582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">45 Wiggins Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bedford<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">430-8200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STOK<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d55930d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d55930d8k.htm">d55930d8k.htm</File>
    <File>stok-20251005.xsd</File>
    <File>stok-20251005_lab.xml</File>
    <File>stok-20251005_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d55930d8k.htm": {
   "nsprefix": "stok",
   "nsuri": "http://www.stoketherapeutics.com/20251005",
   "dts": {
    "inline": {
     "local": [
      "d55930d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "stok-20251005.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "stok-20251005_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "stok-20251005_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-10-05_to_2025-10-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d55930d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-10-05_to_2025-10-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d55930d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.stoketherapeutics.com//20251005/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-25-230925-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-230925-xbrl.zip
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M^C_[/J!FWH/Y!?4&OLON?V7S2@Z^D@8/@_/< A%ZUSQL-]\MP]=80)-@8R9
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MT@F9B. NFJ)3'&)&GDKBLC'W]79VG=^TVF3Y\$QV9N:0'"!]CTYUDC-I#?,
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M248ZS5:8U,<$=Q!@XF.-<]X\/*ZVFH]P]XHI%^C$A8X=%1O"K(DS:C32E&>
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M,NU8I^3?LD'2X%[P;>N4'?IU&)T3,U[ "[GP$_"2! GYZ_#M#> '] -42AD
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M1M65+OTE+G+H_'3CH*8<.B>>R;+NT;9,\SB!3;0&IT-8+&"Z:5[I)Y/YH$C
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M<F8/]@P",P'9B"5UG6$JPI>J.,.&@6,VCY4!?B$*3QORHA@EDH8*SAUN+&*
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M>=MYFE$&P;@]+]KGEKS$IMT"C1>P/OAD(2C['B?.-3KU:P$_:ZB.!CR=Z,E
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M\.IB7WXX-F]^^N*'-6#8JV/WE]]D!WAM;H[FBXT!OO1Y.P'XSX4W54,#[SR
MT$QB. \(#XSN28/&Y& ?UVBW&^QFWAJ%^QTM%AMWG< )R-W+*9@ZR"$^(1KT
MLGS4_@9-^@L>_:KK):>6G-2#=WUP:8\N>]')V=&673[M=[C7WAC>GKWIH_\+
M'/0\7+WW.;CJ>,Y@8;OW^$['#/YF;KN3#-W!CP9Y 2:K^^A31(W#HW]LT_^^
M4*@^*9]$CX0A'Q-)#L FKXOHZL]$9: 5RF6\^K]%+EF+[#]$+AW.]Q[+/O\'
M4/L*<X1[U-R@2/Q>^$<3E13_T;K@J^T!M@[:B\Z'53X =_%9+]K=WGWV<*?=
M-_;@'[23OTW';W>YX_?JR>'Y\>_PX9NKMZ?[_Q]02P,$%     @ QSM&6Y[X
M9/S'&P  ;G   !    !D-34Y,S!D97@Q,#(N:'1M[5UI3^/(UOX>*?^AQ&A&
M00JAH=>A&:0 F89[:4 AW7WG_5:Q*TG-.':N%R#WU[]GJ2J7'0?H%4::5JN;
M.':YZM19GK,5^R>C]V<'^R>#_O%!N[4_.AV=#0X&_]G:>=;;W=_FCW!]V]P@
M]@\OCO\0A^^.+LXNAK]M?#HY'0TVQ-7HC[/!;QN1CM763.GI+-\[3]*YC#8.
M1+L%SQ^I.%?IP?[QZ4=[\XT.\]G>F]Y+'6\(&>EI# .H2;Y!K[FTM\UE.M7Q
M5IXL]IXM\K?"?!XG>9[,^=(DB?.M3/]/[>V4GR=RKJ/EWDC/52;.U8T8)G,)
M;^J?G;X[_VTCQ4EN'.P?'@QN9WJL<X$K%OO;AP?[VY>XY*89[.Q^PRD$1).-
M@Z.3_OF[@;CX71Q=G(^&%V?B:O!Q,.R?'PU$_]UP,'@_.!^)+YE5KF[S+1V'
M\**]%S]_V2S_++)<3Y8;!Z.9SL313,93)9*).()GTR025^I:I3(.E.A/4Z7F
M\"[1R6=*_/+3F]W=9V_=5?J\\W:S*V"<N0R5D'$HB 8J%#K.$Y'C*U[E,Q'*
M);[C(LB3L4J[[=;NL]V7E6$'DXD*<GVMQ+',53GV>$G#CE5^HU0LKO+D+R5&
M,YCB0A6Y#K*N.(V#GNB8<>B&\G%\%GCB5,*C<YW/D!_<O8-;%13X3GM_[ZY=
MV7WQ'7AE_\/!4 4ZEU&VO_WA8._QV6+_=V!:)],SG:NM;"$#M1<G-T#TC8/A
MUDYO?QOO.C#;@41VM!0R56(ATUS#>X '@/*#^2)*EL1))4^%L,VA2&*1I$*.
MDR(';E'M%EX6L+TJF72K#-(P2-=LG(!Y!C.@0SH7V4Q&$;!?$!7 DCA X^ME
M)D!'S($OQS!EN!3";"9I,A<Y4 @G3O_C3.0$!KZ;-Y[,UNS6MN9&9S/>AT6:
M7&N@2+E1-R /(E!I+G6,7\]U!K>RM,5JHG,@44P4!)40Y^T6#XE4UC%L4R8J
M K3S^FTF5$EK'!ZW]4@6F<)=+M_\T"$F\-2[) G%4,DLB;LTIIG30J4ZP:D"
MR6,=3P7\H_*EZ/SZ;/.7>)PMWH+2R6!=&@8A/D3E%.*=2:Q$9\?<M50RA1=%
M47*#W\E5E=A#>WEYT&S#?LS.GU]\ZHK1R6 X^/UB..CBO@1)G,%^IC+7*$03
M(LJ\R L9N<WL$J5Y3^'^4..]9E=!,WO2 #<D,$ JIDAN^-AN7<NHD.-(5=_4
MI?>D*E!ZP<]EQ62B ZWB@'0\BR(J 90=4-\\IPCT>/ 7,&JDPJD*>1BK)B1.
M!$62]R%[ FIP!^3]P\$QB$',5$/U?*<.>/4CIM61FZ(/^BV0"S0:,$IH]AB$
M+%RSLW&2\^Z"-E BQ#7!O;@]<#_KRYF\9F4Y5Y*D269!JL<X.IIQ-8>AVZU5
M86W2K4RE9G'Y,40:;^+FK0@R;V%_':T +5ACXQYMM\RSUM(PN9!*1*XD"(HT
M50B7X#TR7EI)+#4**4\01:. @:(SF9,(*PF2$LB,GNUHHY!PQSI:;[*(Y(#%
M,AF0D'?8JM'VP)LRT(! "'QA>5.V"=@[2\1_0>;TA(0+_HJ %\1Z@W!> <1.
MQ8?>54^,P,9E1;H$-3LM(E8H;&M YZ^W-CN]%\]^[6\]AYEW7F[N6</S^9MO
M+J&S0)O_;9E!$S-<W,0JS69Z89@ Z&?V^A*N)['=WPZ0*RN"6;M%:$*7S'*E
MF,!BYWDGW"3!VGF!/YD=A^^+5),^&]P:>O>#'+_>^?7YBRYM! .-33!;08(3
M]P#.(1G=0(/^ILGZ,[(R"],8%J"2[T4".\_#K>=V1WBK,ZE#G! P5JA!@>>@
MDL$T IW-IR[Q>U8N V;.)C]5BU1EL!W(>A,] 3,+YC<@U^#ELY\W<9QYDBI+
MBCP!W22N$[I_D=S V]T0L HP"@ZFDQ:!9\"$%7F62[;0YE%O+AUU:WD?40%)
M[J)(%TFF6!A@SQH>FZFH?%^7L";<+,%B11KP1Q=-$"XC26'EQ1CLG);ITJV<
MGB 79&EP"=@I@X[$(I*QNW,39Y,5$L9"L%&16WRK)ZVIB@C[^E)KS&:5+(>)
M3$-\XIAV*$FS"B*FKZWK(L($1D=-+Q>H:=1;?.T7F*OO+(PLC>]5.E7I]I6,
MB&?Z6:9R8V$[?:,'^Z!E\2Y<!T*0)-*A SL&W<X4@1:XPULY;3@Y$T2AKD$V
MH'9CV(=U@_(&W"0%, QP:A'E%OVN<I6;@,^S>CY7(3(5R)5!G6AB@1M0Y>JX
MP)O@DY,$X&E-,X/IIFH.*)S J3<D,]]8X<\P"#CFN76M&R=%BP9-?JVOR?+
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MWH[!0%#S"O5X * &44,7,$.6D;(.8+-@]]*EX;K_%AJ3 +F\-5,HE<N6A;_
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MEI RIBS'NFC30E(M ;,[+(*ES::S\ +B? +^5+";94G @60N.?4+D1RW@XV
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M6X>%SPYX? 3.9^E\DNB$,Q&P'>A+"42ID!L<+.S:,QA4;)$G>ONX_H*,-1"
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M=E<K^T/L#[N\/S\ +\[ ]HC[^"<^_NS]0?$_61'_ 1.M;EY+9K3G7EX3Q6E
MNJJ$X^%U>42^JC>']>#SL-_Q]C[IO0:?7"GM@J,Q$]XT0LUU?T67OHF+H9.G
M.(>PQPIN2J,E[M]VK#&Z0>,$K?W'8>@,+ W.3R._>.)ASWR3?);0GAE4GCC8
M'"\O9@1!>?U(;\ ZX3SXVHO!R^G]Y')MVK<#>:>\R]%X_L_A-@9_-%R"6%KS
MH6R[H_YCI/7#P7L_MZ0!_O!U>G7 0[%^*9CC#UKI>M6QO=!EZU^EX?M<59\4
M<5Q=48N9.O"+0-"3,B7U;P>IK]D.?"NDOW4B]#%1H _]ZQLLC(]<5="9@Y&]
M$[9M9-M^:['Z79V%<\EEV<IU]GMPK[$/N%VWPY&/S';C^MNA<L,\L^V![F_&
M@]]==8N'?OX#4$L#!!0    ( ,<[1EL>IEPY6P8  +U#   5    <W1O:RTR
M,#(U,3 P-5]L86(N>&ULS9QM3^-&$,??GW3?89J^::5S0H)H102<:( *E2=!
MKJU:52?'7I)5G=UHUX'DVW?7#X=#ULZ:'=>\N#MCS_QG_LYO?!O'X>CS:A[!
M$Q&2<G;<Z7?W.D!8P$/*IL>=I?1\&5#: 1G[+/0CSLAQ9TUDY_/)QP]'WWD>
MG%U<WH 'LSA>R&&O]_S\W T?*9,\6L9*4G8#/N^!Y^7QH_$7^#TM-X1[$A%?
M$A@<] ?PRY)&X7"P-SC8^WDPZ/:+28+X6@U"/R9#Z._U?NKI0+4UW#L8#@[A
M]!K.?1D3P6!,YZ28RQ=K0:>S&'X(?H0DZXPS1J*(K.&",I\%U(_@(6_X$URR
MH NG403W.DVJ+B413R3L9JH19?\.]5\3W3M\_ "@3B*3R;[CCCX5V9E83434
MY6*JFMW;[^4IG9>,U5;*\WZ2T#\\/.PE1XO1DIIBE7B_]^?UU4,P(W/?4R=?
MO5A!5D;2H4SV7_$@.8<6#4)IA/[)R\,\O<OK#[S]?G<EP\Z)+IB='7]"HBNU
M!8F'H> 1J2BL#R?5.UE\O%ZH>+**"0M)IOQ-FP=9U$R0QU15HY=(2A)TI_RI
M%Q*:$*(W/+VA._Q>_?!UQ!7MIQ,9"S^(-^M%^A1QD>],3!QW#$F]S89TW*D(
M-K1\$>0Z:G.'_RRB%W#UNBUB+U',TQ\%GQN[R,IQP\&OT20RMJE)4EMZN GS
MOCSL\IH*%8T)(OE2*+SJO+2)GY-$&?[.M?\YZKW4?B^MJDN()%=U^W5#\G2N
M,%=_XHO(G]HB^2JI)23-K7/#01<D#4)(2'Y3!BWM#&0#C1:!M.W6#<=S%M-X
M/5)EA!]=J@OPZC>RML6R)+DE/*NM\(H@%UPK!)&P32M 5@*2&J"*. /<8.M%
MD.OW[X;T&0^6>F[&JGM;DC=S6@+8V#C?/N:"Z[8.$J6Y,&AE9S3QVRP2:=DK
M#H9W1% >GK/P3+V?J<OCJ^26P31;X15!&*@:!+&934N J@&Z"!J^#;1NY-BZ
M?XS%PCV94KU(9O&-/[<FVIS;ZE*AQ @OCW%?*)CT<-<)+Q5 ET!:)331MV&1
M8-T\!LB7+.!BP45RJ^0A5H,SXDNU2%F/>%B3ZQU2K6)N9Y-;I[@/@84\[DQL
M%(2D(F0E0==$&I+_P9=A9MYN#F.(+FA$;I;S"1'U)J:8U^IX& QP\W%W\%]K
MX5*NU2&51P(:NU\#O59-8X Z]E>7H5HLT4>:WAQ_"[6E(JTBO,L:MPAVA[M2
M&)=T50HV:^%RWZ@5PQ"\P0_&2)R&H3(@LW^N*"/]>N-@%&AU%*HL\1V![B-0
M*HJ+?Z;_*=\ 70EN&=8ZIC$;!O3?X 41_9':O!5C_LS>!'XQ_3U@;[!C@OXE
M# WYUY(- :_+ !>@"^'"CFV@"G4[%XB8)V\*;L6=X$^4!37?VY9IO ?@RXR9
MJ'\5BX:^4;<A_M-W=PJ=O!KN$#1BI6H2:OA!'(<[+F,_^HLNZM_H,2N\AU$P
MFS(-PD8DVA@85!L:@K02J%*8-V^:LU$U -9>'!^$T@8%\>L OYG3UF-0IL;Y
M]C&GAZ"V=)# 3?Z?U\HXG.+WN?$ E&6S;B#J)Q.CNQEG-6\:;N>U!&2I 6X^
M[@*F60L)SD0<$G6LFR?-]%N$M$[3;J#^(6@<$S;B\_F293=EI"VM)<DM(5MM
MA5<$N<!;(8A$<%8!-DLX4]Q@XT64ZW;OAO,#CVA 8\JFUVK%+:@?V;)LRFP)
MY H3O"S"!>$R-21^7^0AUW>&MZF6B^36ZML-VSM!]'P0A47R.)C^BH"X?7RT
M7SA4*;2$L84IOBO2!>M=JDAXJS)0K -I(4@J.8/>M(DB\&]T@HK^I91+(MP'
MP*#S/L:@W*!Y&+;B$4>B1+NIP4C+-3H?#3FJG)):MAR7-R18JO74NC^8C&D<
M6=_CV,YK:VE39H";CSLM:XQ:6(N:3!R4.B3R[FN:1OK=6-'4:-H-U+'P]==M
M'];S";=>@K]*:@E1<^O<<- %3H,0$IF9,J32SE0VT&@12=MN<:Z;YZM@IMR2
M.D]TFW-;OGX:C?#R&(SKZ+8>]K4TKX#S1'=S?1NOJ9;-8WR^=SXG8JJFYE?!
MG^.96HPL?%;SVXPE$JU^PE=MB^\,=?^,KT(6B?7L@[&\$*25("N%]!E?@S8,
M'_+9>BGNN%);^O=.9+MH^ML7U)[_ %!+ P04    " #'.T9;RV:QW[8$  "-
M*@  %0   '-T;VLM,C R-3$P,#5?<')E+GAM;-6:78_B-A2&[U?:_^"F-ZW4
M$,+L[';0,"O*S%2H\R5@VZHW*Y,<P%K'CFPSP+_O<< 5@3 +TVT5S\40'+_'
M[SF/,8G)Y<=EQLDS*,VDZ 1QHQD0$(E,F9AV@KD.J4X8"X@V5*242P&=8 4Z
M^'CU]LWE=V%(KF_[#R0D,V-RW8ZBQ6+12"=,:,GG!D/J1B*SB(2AZ]\;?2*_
MKX=KDP%PH!I(ZSQND5_FC*?M5K-UWOS0:C7B;9$":J.1E!IHD[@9O8]L1SQJ
M-\_;K0O2O2<W5!M0@HQ8!MM:F:\4F\X,^2'YD12J:RD$< XK<LL$%0FCG R=
MX9](7R0-TN6<#*Q,HTL-ZAG2QB8J9^)+V_X;6^_D[1N"?UA&H8O63F"+L:G%
M<JQX0ZHIVFV>14X4;&N6>Z+%62&)+RXNHN)LN;]F5;UQ@#CZ\_YNF,P@HR$B
M0&3)SE#H)C7_J+?-G4?KDZZ_9FU=1+J325'[(](B!WO8=Z'K%MJF,&Z%9W%C
MJ=/@R@ZYKJJ2' 8P(?;UTZ!?&E,;^07,#!3- 5$EZZE5S(/8^C=T*87,5I$5
M1]<RF6<@C'OMBO1&&&96?3&1*BM2"DA1W?9,P:03V/BABV:-?3_ 0)]/"616
M.7X^-,MR#@&)MA++%4XB88K>=]A0$L#2@$@A=6%L O]UZE=KSIO)+)-2*=RG
MN8"H(6E,Y7.4 BM&M =%G8H:X9O//8D+2'>LC:*)*=>"V]DCE6OD= R\$U2(
MHF]IJ(MIIS;U6TZGQQK:$94-;?/KJJ04DJK$A</#/7CE3\*F1Y13A?'"9(:+
MGE-/E,PJB[,9358:E2H%U0EPR<05(""Y8E(A;&P)R%RC%YE;UY3;<S !I2"]
M6Z=]T&5A$5=3#47/;XQG/1M[F(&BO(\S?_D;K([%=$!<7UP'##ML9]Y@<^O)
M",MX+*VRIKZ0RCX=FW/OV#P!>L7E/KW&*Z53(>V(ZT]KQ[##]MX;;.NU80!3
M9A,5YH%F1U.KUM876K5?Q^R#9\SP)D&J7*JBM$.L,/3D')?X54^F)R+\2JBZ
M$_V*?0?X9\\ WS(.#_-L#.HTFMNZNJ/;]NHX77C&:427_13+P"9L?:/Z&F@'
M@]2=X$'C&YQG3<]P=M,4BZPW+WBK#/%I*"L#U!UCI6F',/8380\/']5(+L2K
M &[+/<&W;=G!\^VN?)-*\3W^J)Z4?&9V%_$U!/=B>()QS[=CZ<^M>BF?)ZD-
MY7^Q_/1+T^H(GG#<<>THOO.&HEU/N@KH*=S*FOJ2*OMT;/S9<+$_B_"GF10G
MWB3LZ^K+:-^KX^3/#LL?Z,^ Z,DLFXO--;(^%M8!<7V)'3#LL/FSR3*4G"7,
M,#&]QR]CQ:RUXYA5*>L+K,JMH^7/CLF3 COE *^6BDUT^VNF>IQ,CE\67XI0
M7WHON784_=E/V<FFK_4<U+]G61''&Z(5WC=<W_FSL3*$9&XMQJWQB!E^]*7D
MOJZ^W/:].D[^[)Z,%+6/70U7V5@>_76W(ZHOH1VC#H\_^R-NBMTLDQD54SCE
MM[IJ;7UA5?MUS'S;![G)0$UQ[OVJY,+,<'W/J3CQ>9,#(>I+\$7;#N3_L!5R
M&>V5Y@X;['.4ZS/VGWTJ$%O^!E!+ 0(4 Q0    ( ,<[1EL<1]>NEQ<  !"(
M   -              "  0    !D-34Y,S!D.&LN:'1M4$L! A0#%     @
MQSM&6^6M:H+E+P  "-\  !               ( !PA<  &0U-3DS,&1E>#$P
M,2YH=&U02P$"% ,4    " #'.T9;GOAD_,<;  !N<   $
M@ '51P  9#4U.3,P9&5X,3 R+FAT;5!+ 0(4 Q0    ( ,<[1EL1[H9B/P,
M &8+   1              "  <IC  !S=&]K+3(P,C4Q,# U+GAS9%!+ 0(4
M Q0    ( ,<[1EL>IEPY6P8  +U#   5              "  3AG  !S=&]K
M+3(P,C4Q,# U7VQA8BYX;6Q02P$"% ,4    " #'.T9;RV:QW[8$  "-*@
M%0              @ '&;0  <W1O:RTR,#(U,3 P-5]P<F4N>&UL4$L%!@
0   &  8 ? $  *]R      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d55930d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="stok-20251005.xsd" xlink:type="simple"/>
    <context id="duration_2025-10-05_to_2025-10-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <startDate>2025-10-05</startDate>
            <endDate>2025-10-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-290">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-10-05_to_2025-10-05"
      id="Hidden_dei_EntityCentralIndexKey">0001623526</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-301">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-302">2025-10-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-303">Stoke Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-304">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-305">001-38938</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-306">47-1144582</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-307">45 Wiggins Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-308">Bedford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-309">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-310">01730</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-311">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-312">430-8200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-313">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-314">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-315">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-316">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-317">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-318">STOK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-319">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-10-05_to_2025-10-05" id="ixv-320">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
